Plain-English translation of NCT06948929 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Alzheimer Disease research guide →This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This pilot study is testing a new synbiotic formula called SCV09—a combination of beneficial bacteria and compounds that feed them—to see if it can help improve behavioral symptoms and cognitive decline in Alzheimer's disease patients. Researchers believe the gut microbiota (the trillions of bacteria in your digestive system) may be connected to brain health, and this medication is designed to support that gut-brain connection. This is an early-stage study with 30 participants to gather initial evidence before testing the treatment in a larger group.
Recent research suggests that the balance of bacteria in your gut may play a role in Alzheimer's disease and other brain conditions. This medication aims to restore healthy gut bacteria in a way that might help slow cognitive decline and reduce difficult behaviors—offering a new approach that hasn't been fully tested in Alzheimer's patients yet.
You likely qualify if…
You likely don't qualify if…
You would take one sachet (a small packet) of the supplement mixed with fluid by mouth once daily for 6 months. Your caregiver will help ensure you take it regularly and will collect stool samples at certain times to monitor how the treatment affects your gut bacteria. You'll attend clinical follow-up visits so the research team can track any changes in your thinking, behavior, and mood, and watch for any side effects. The study is small and exploratory, designed to see if this approach is safe and shows promise before a larger trial is planned.
AI-generated summary from trial data · Jun 4, 2026 · Not medical advice
Hong Kong